IB Acquisition Corp（IBAC）資訊與事件IBACIB Acquisition Corp

GNQ and IB Acquisition Corp. Announce Business Combination Agreement

GNQ Insilico, a corporation formed under the federal laws of Canada, and IB Acquisition Corp., a Nevada special purpose acquisition company, announced that they have entered into a definitive business combination agreement, pursuant to which IBAC will acquire all of the issued and outstanding shares in the capital of GNQ by way of a statutory plan of arrangement under the Canada Business Corporations Act. Following closing of the transaction, which is expected in the third quarter of 2026, the combined company expects to be publicly listed on Nasdaq. Shares will trade on Nasdaq under the symbol IBAC until the closing of the transaction. "GNQ's mission is to revolutionize drug development by leveraging artificial intelligence, digital twin technology, advanced biological modeling, and quantum computing to enable precision medicine at scale. By transforming how pharmaceutical companies discover, develop, and optimize therapeutics, GNQ empowers partners to accelerate development timelines, reduce costs, and deliver improved patient outcomes across multiple disease areas," the company stated. Rehan Huda, the Founder, Chairperson, and Chief Executive Officer of GNQ said, "Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered Drug Assessment, Drug Simulation and Digital Twins Platform to transform pharmaceutical R&D and healthcare delivery. Our platforms address critical inefficiencies across the healthcare value chain, enabling smarter investment decisions and accelerating drug development to deliver truly personalized medicine. This transaction provides the resources and public market visibility to expand our commercial partnerships and scale our solutions to serve pharmaceutical companies, investors and healthcare providers worldwide. We are excited to work with the IBAC team as we execute our vision of making precision medicine accessible and economically viable for patients worldwide."

IB Acquisition Corp Trading Halted, News Pending

IB Acquisition Corp trading halted, news pending